The optimal diagnostic strategy to identify tumors harboring RET gene fusions, RET point mutations, or other actionable driver mutations in malignancies, including ATC, is, therefore, a broad-based NGS approach combining analysis of both tumor DNA and RNA. The gene discussed is RET; the disease is neoplasm.